Farmaceutica Remedia SA

The company maintains a strong liquidity position, with cash and equivalents amounting to RON 57.9 million, representing 15.1% of total assets. The liquidity FPT (free cash flow to total liabilities) is 1.87, indicating a robust ability to meet short-term obligations. The current ratio of 1.11 is slightly below the median for the Drug Retailers industry, but the low debt-to-equity ratio of 0.01 suggests minimal leverage risk. Profitability metrics show a return on equity (ROE) of 10.1%, which is above the industry median of 7.8%, and a return on assets (ROA) of 2.1%, slightly below the median of 2.5%. The operating margin of 1.94% is in line with the industry median, but the net margin of 1.06% is below the median of 1.3%, indicating potential inefficiencies in cost management or tax optimization. The company operates in a single business segment, with all revenue derived from its pharmacy and drugstore network. Geographically, it is concentrated in Romania, with no disclosed international operations. Revenue is distributed across 13 Romanian counties, with Bucharest and Cluj likely representing the largest contributors due to urban population density. Outlook data indicates a projected 4.2% revenue growth in the current fiscal year and 3.8% in the next, driven by expansion of its logistics network and pharmacy footprint. Historical revenue growth has averaged 2.1% annually over the past five years, suggesting a stable but moderate growth trajectory. Risk assessment shows low liquidity and dilution risk, with no immediate filing-based flags detected. The company has not issued new shares in the past 12 months, and no dilution adjustments were applied in the valuation model. The low long-term debt of RON 750,530 further reduces refinancing risk. Recent filings and transcripts show no material changes in business strategy or financial position. The company continues to focus on optimizing its logistics centers and expanding its pharmacy network. No significant regulatory or legal risks were disclosed in the latest 10-K equivalent filing.